



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2013

(₹ in Lacs)

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2013.

PART-I								STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2013.					
SR. No.	PARTICULARS	STANDALONE				CONSOLIDATED		SR. No.	PARTICULARS	STANDALONE		CONSOLIDATED	
		QUARTER ENDED		YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED			Mar-13	Mar-12	Mar-13	Mar-12
		31.03.2013 (AUDITED)*	31.12.2012 (UNAUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)						
1	Income from Operations	10012.71	8131.68	7071.52	34810.82	26442.53	39083.23	26442.53					
	(a) Net Sales (Net of Excise Duty)	260.70	106.24	86.80	557.60	264.63	579.31	264.63	1,031.47	1,031.47	1,031.47	1,031.47	
	(b) Other Operating Income								24,842.03	20,011.63	24,769.10	20,034.12	
	Total Income from Operations (Net)	10283.41	8238.92	7158.32	35368.42	26707.06	39662.54	26707.06	25,873.50	21,043.10	25,800.57	21,065.59	
2	Expenses												
	A) Consumption of Raw Materials	5606.68	4667.95	4262.77	18848.51	14789.48	20131.89	14789.48	5,367.81	294.19	8,821.44	3,762.83	
	B) Purchase of Finished Goods	52.50		217.82	360.28	1001.28	872.44	1001.28	426.68	120.17	487.94	120.17	
	C) (Increase)/Decrease in Stock in Trade	64.85	-440.05	-40.36	-511.73	-53.60	-823.16	-53.60					
	D) Employee Benefit Expenses	272.80	282.49	207.28	987.07	884.43	1607.85	703.95	73.81	51.38	73.81	51.36	
	E) Depreciation / Amortisation	119.71	105.86	85.53	442.78	364.61	802.54	364.61					
	F) Other Expenditure	2877.22	1328.85	989.27	5604.99	3204.48	6836.36	3212.90					
	Total Expenses	8634.39	5845.80	5871.11	25732.90	20018.68	29127.72	20028.83	5,878.31	465.72	10,483.19	3,934.46	
3	Profit (Loss) from Operations before Finance Cost & Exceptional Items (1-2)	1628.02	2391.12	1487.22	9635.52	6688.38	10534.82	6688.38					
4	Finance Cost	731.82	226.65	412.57	1503.28	1665.85	1408.99	1575.13					
5	Profit from ordinary activities before Finance Cost (3-4)	2360.84	2616.77	1898.79	11138.70	8222.24	11943.80	8253.56					
6	Finance Cost	221.13	196.80	82.00	665.47	310.80	983.58	311.83					
7	Profit from ordinary activities after Finance Cost but Before Exceptional Items (5-6)	2139.71	2419.91	1887.79	10483.23	7911.25	10960.24	7941.93					
8	Exceptional Items												
9	Profit (Loss) from ordinary activities before Tax (7-8)	2139.71	2419.91	1887.79	10483.23	7911.25	10960.24	7941.93					
10	Tax Expense (Including Deferred Tax)	1569.28	1481.02	1041.11	4815.03	2688.35	4968.79	2088.35					
11	Net Profit after Tax & Minority Interest (9-10)	570.42	938.89	846.68	5668.20	5222.90	5991.45	5853.58					
12	Minority Interest												
13	Net Profit after Tax & Minority Interest (11-12)	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47					
14	Paid - Up Equity Capital												
15	Reserves Excluding Revaluation Reserve (As Per Balance Sheet)				24842.03	20011.83	24789.10	20034.12					
16	Basic and Diluted Earnings Per Share	0.55	0.51	0.78	5.30	5.32	5.48	5.48					

PART-II								STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2013.					
SR. No.	PARTICULARS	STANDALONE				CONSOLIDATED		SR. No.	PARTICULARS	STANDALONE		CONSOLIDATED	
		QUARTER ENDED		YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED			Mar-13	Mar-12	Mar-13	Mar-12
		31.03.2013 (AUDITED)*	31.12.2012 (UNAUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)						
1	Aggregate of Non-promoter Shareholding	38186842	36187842	36187842	36186842	36187842	35186842	36187842					
	- No. of Shares (Face Value Rs.1/- Each)	35.08	35.08	35.08	35.08	35.08	35.08	35.08					
	- Percentage of Shareholding (%)												
2	Promoter and Promoter group Shareholding												
	A) Pledge / Encumbered												
	- No. of Shares (Face Value Rs.1/- Each)												
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)												
	- Percentage of Shares (As % of the Total Share Capital of the Company)												
	B) Non Encumbered	68958830	68958830	68958830	68958830	68958830	68958830	68958830					
	- No. of Shares (Face Value Rs.1/- Each)												
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00					
	- Percentage of Shares (As % of the Total Share Capital of the Company)	84.92	84.82	84.92	84.82	84.92	84.92	84.92					

SR. No.	PARTICULARS	Quarter Ended 31 March 2013
1	Investor Complaints Pending at the beginning of the quarter	-
	Received during the quarter	1
	Disposed off during the quarter	1
	Remaining unresolved at the end of the quarter	-

SALES UP

₹ 8368.29 Lacs

PBT UP

₹ 2511.89 Lacs

EPS

₹ 5.50

FOR BLISS GVS PHARMA LIMITED

SD/-

S. N. KAMATH

MANAGING DIRECTOR

Place : Mumbai
Date : 28th May 2013

Size: 28 cms (w) x 34 cms (h)

PART - I

BLISS GVS PHARMA LIMITED
 Regd Office: 102, Hyde Park, Sakinaka Road,
 Andheri (East), Mumbai - 400 072
 AUDITED FINANCIAL RESULTS
 FOR THE QUARTER / YEAR ENDED 31.03.2013

SR. NO.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED				YEAR ENDED		YEAR ENDED	
		31.03.2013 (AUDITED)	31.12.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)
1	INCOME FROM OPERATIONS (a) NET SALES (NET OF EXCISE DUTY) (b) OTHER OPERATING INCOME	10,012.71 250.70	8,131.68 105.24	7,071.52 86.80	34,810.82 557.50	26,442.53 264.53	39,083.23 579.31	26,442.53 264.53	
	TOTAL INCOME FROM OPERATIONS (NET)	10,263.41	8,236.92	7,158.32	35,368.32	26,707.06	39,662.54	26,707.06	
2	EXPENSES a) CONSUMPTION OF RAW MATERIALS b) PURCHASE OF TRADED GOODS c) INCREASE/DECREASE IN STOCK IN TRADE d) EMPLOYEE BENEFIT EXPENSES e) DEPRECIATION / AMORTISATION f) OTHER EXPENDITURE	5,606.69 52.50 -94.65 272.90 119.71 2,677.22	4,567.95 -440.05 282.49 195.86 1,329.55	4,262.77 217.62 -40.36 207.28 65.53	18,849.51 360.28 -511.73 987.07 442.78	14,799.48 1,001.29 -53.60 694.43 364.61	20,131.69 872.44 -673.16 1,507.85 602.54	14,799.48 1,001.29 -53.60 703.95 364.61	
	TOTAL EXPENSES	8,634.39	5,845.80	5,671.11	25,732.90	20,010.68	29,127.72	20,028.63	
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)	1,629.02	2,391.12	1,487.22	9,635.42	6,696.39	10,534.82	6,678.43	
4	OTHER INCOME	731.82	225.65	412.57	1,503.28	1,585.85	1,406.98	1,575.13	
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)	2,360.84	2,616.77	1,899.79	11,138.70	8,282.24	11,941.80	8,253.56	
6	FINANCE COST	221.13	196.86	92.00	655.47	310.99	993.56	311.63	
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)	2,139.71	2,419.91	1,807.79	10,483.23	7,971.25	10,948.24	7,941.93	
8	EXCEPTIONAL ITEMS								
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7+8)	2,139.71	2,419.91	1,807.79	10,483.23	7,971.25	10,948.24	7,941.93	
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1,569.28	1,481.02	1,041.11	4,815.03	2,688.35	4,989.78	2,688.35	
11	NET PROFIT FROM ORDINARY ACTIVITIES (9-10)	570.43	938.89	766.68	5,668.20	5,282.90	5,958.46	5,253.58	
12	MINORITY INTEREST						-186.45		
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11+12)	570.43	938.89	766.68	5,668.20	5,282.90	5,772.01	5,253.58	
14	PAID - UP EQUITY CAPITAL	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				24,842.03	20,011.63	24,769.10	20,034.12	
16	BASIC AND DILUTED EPS (NOT ANNUALISED)	10.55	10.01	10.74	10.55	10.55	10.55	10.55	

(Rs. in Lacs)

PART - II	PARTICULARS	STANDALONE						CONSOLIDATED	
		QUARTER ENDED		YEAR ENDED		YEAR ENDED		YEAR ENDED	
		31.03.2013 (AUDITED)*	31.12.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)	31.03.2013 (AUDITED)	31.03.2013 (AUDITED)	31.03.2012 (AUDITED)
A	PARTICULARS OF SHAREHOLDING								
1	AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS. 1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	36186842 35.08	36187842 35.08	36187842 35.08	36186842 35.08	36187842 35.08	36186842 35.08	36187842 35.08	36187842 35.08
2	PROMOTER AND PROMOTER GROUP SHAREHOLDING A) PLEDGE/ ENCLIMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (% OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (% OF THE TOTAL SHARE CAPITAL OF THE COMPANY) B) NON - ENCLIMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (% OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (% OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	66959830 100.00 64.92	66958830 100.00 64.92	66958830 100.00 64.92	66959830 100.00 64.92	66958830 100.00 64.92	66959830 100.00 64.92	66959830 100.00 64.92	66958830 100.00 64.92
B	INVESTOR COMPLAINTS	Quarter ended 31 March 2013							
	Pending at the beginning of the quarter	-							
	Received during the quarter	1							
	Disposed off during the quarter	1							
	REMAINING UNSOLVED AT THE END OF THE QUARTER	-							

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2013.

Particulars	STANDALONE		CONSOLIDATED		(Rs. In Lacs)
	Mar-13	Mar-12	Mar-13	Mar-12	
I. EQUITY AND LIABILITIES					
SHAREHOLDERS' FUNDS :					
(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	
(ii) Reserves and Surplus	24,842.03	20,011.63	24,769.10	20,034.12	
(iii) Money received against share warrants					
Sub-total - Shareholders' Funds	25,873.50	21,043.10	25,800.57	21,065.59	
Minority Interest			1,379.86	0.49	
2					
Non-Current liabilities					
(i) Long term Borrowings	5,367.81	294.49	9,921.44	3,762.93	
(ii) Deferred tax liabilities (Net)	436.69	120.17	487.94	120.17	
(iii) Other long term liabilities					
(iv) Long term provisions	73.81	57.36	73.81	51.36	
Sub-total - Non-current liabilities	5,878.31	465.72	10,483.19	3,934.46	
4					
Current liabilities					
(i) Short term Borrowings	1,820.75	222.11	5,604.24	590.47	
(ii) Trade payables	9,242.53	4,011.69	11,936.28	4,015.13	
(iii) Other current liabilities	1,381.65	533.20	1,781.05	610.19	
(iv) Short term provisions	1,422.24	758.35	1,527.49	758.35	
Sub-total -current liabilities	13,867.16	5,525.35	20,849.06	5,974.14	
Total	45,618.97	27,034.17	58,512.68	30,974.68	
II. ASSETS					
1					
Non-current assets					
(a) Fixed Assets	4,944.16	4,065.91	16,887.92	4,693.58	
(b) Non-current Investments	1,922.02	23.10	1.01	0.01	
(c) Deferred tax assets					
(d) Long term loans and advances	9,367.29	1,996.62	5,323.74	5,327.82	
(e) Other non current assets	241.20		241.21		
Sub-total - Non-current assets	16,474.67	6,085.63	22,453.88	10,021.41	
2					
Current assets					
(a) Current Investments		80.26		89.26	
(b) Inventories	2,458.45	1,268.09	3,252.33	1,268.09	
(c) Trade receivables	21,821.11	12,859.02	25,748.88	12,859.02	
(d) Cash and Bank balances	3,081.57	5,790.40	4,971.82	5,890.56	
(e) Short term loans and advances	1,357.25	781.71	1,694.25	787.00	
(f) Other current assets	425.92	169.06	391.52	158.34	
Sub-total - Current assets	29,144.30	20,948.54	36,058.80	20,953.27	
Total	45,618.97	27,034.17	58,512.68	30,974.68	

NOTES:-

1. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
2. THE CONSOLIDATED RESULTS INCLUDES THE AUDITED FINANCIAL RESULTS OF PARENT COMPANY, THE SUBSIDIARIES NAMELY BLISS GVS INTERNATIONAL PTE LTD (100% HOLDING), BLISS INDASI LIFE SCIENCES PVT LTD (51% HOLDING), BLISS GVS CLINIC HEALTHCARE PTE LTD (100% HOLDING, KREMINT PHARMA PVT. LTD. (70% HOLDING & ITS STEP DOWN SUBSIDIARIES
3. TAX EXPENSES FOR THE QUARTER ENDED MARCH 31, 2013 INCLUDES SHORT PROVISION FOR EARLIER YEARS RS. 721.70 LACS AND YEAR ENDED MARCH 31, 2013 INCLUDES SHORT PROVISION OF EARLIER YEARS OF RS. 1422.66 LACS (INCLUDING MAT REVERSAL).
4. THE BOARD HAS RECOMMENDED A DIVIDEND OF 40% i.e RS. 0.40 PER EQUITY SHARE OF THE YEAR ENDED 31ST MARCH 2013 .
- *5. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2013 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR ENDED MARCH 31, 2013 AND THE PUBLISHED YEAR TO DATE FIGURES UP TO THE THIRD QUARTER ENDED DECEMBER 31, 2012 WHICH HAVE BEEN REGROUPED / REARRANGED, WHEREVER NECESSARY, TO CONFORM TO FORMATS PRESCRIBED BY SEBI VIDE ITS CIRCULAR DATED APRIL 16, 2012 IN LINE WITH REVISED SCHEDULE VI. FIGURES FOR THE PREVIOUS YEAR / QUARTERS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.
6. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 28TH MAY 2013

PLACE : MUMBAI
DATE : 28 TH MAY 2013

FOR BLISS GVS PHARMA LTD

SD/-
S.M.KAWATHI
MANAGING DIRECTOR